Pipeline Database
UB495
Search clinical-stage assets by therapeutic area, modality, target, indication, stage and territory — then inquire on any row that fits your brief.
UB495
IndicationsNeoplasm malignant
ClinicalCN - IND
TherapeuticsOncology
ModalitiesCGT
Exclusive Summary
- Differentiated "Off-the-shelf" UCAR-T Therapy: UB495 employs a dual-target strategy (CD7 & TAA06) to address manufacturing delays of autologous CAR-T and prevent relapse due to antigen escape.
- Manufacturing Excellence & Cost Efficiency: Leverage a proprietary fully automated production platform that ensures high consistency, broader scalability, and lower preparation failure rates.
- High-Value Early-Stage Asset: Currently in the IIT (Investigator-Initiated Trial) to Pre-IND phase, offering an optimal entry point for partners seeking to expand into next-generation allogeneic cell therapies.
Asset Materials
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →